Lumexa Imaging (NASDAQ:LMRI) Releases FY 2026 Earnings Guidance

Lumexa Imaging (NASDAQ:LMRI) issued an update on its FY 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 0.710-0.770 for the period, compared to the consensus EPS estimate of 0.620. The company issued revenue guidance of $1.0 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. Weiss Ratings upgraded Lumexa Imaging from a “sell (e)” rating to a “sell (d)” rating in a research report on Thursday, June 25th. Barclays dropped their price objective on Lumexa Imaging from $15.00 to $9.00 and set an “overweight” rating for the company in a research report on Wednesday, May 20th. Finally, Wall Street Zen lowered shares of Lumexa Imaging from a “buy” rating to a “hold” rating in a report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Lumexa Imaging Trading Up 0.6%

Shares of LMRI traded up $0.07 during mid-day trading on Wednesday, hitting $11.73. The company had a trading volume of 735,580 shares, compared to its average volume of 790,443. Lumexa Imaging has a 1-year low of $6.45 and a 1-year high of $19.45. The business’s 50-day simple moving average is $10.62 and its 200-day simple moving average is $10.94. The stock has a market cap of $1.13 billion and a PE ratio of -19.88. The company has a quick ratio of 1.40, a current ratio of 1.40 and a debt-to-equity ratio of 1.43.

Insider Transactions at Lumexa Imaging

In other news, Director Brett Brodnax purchased 35,000 shares of the stock in a transaction on Tuesday, May 19th. The stock was purchased at an average price of $7.25 per share, with a total value of $253,750.00. Following the completion of the transaction, the director owned 62,027 shares in the company, valued at approximately $449,695.75. The trade was a 129.50% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.70% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of LMRI. Geode Capital Management LLC purchased a new position in shares of Lumexa Imaging in the fourth quarter valued at $1,548,000. Goldman Sachs Group Inc. purchased a new stake in Lumexa Imaging during the 4th quarter worth $18,870,000. TD Asset Management Inc purchased a new stake in Lumexa Imaging during the 4th quarter worth $1,264,000. JPMorgan Chase & Co. acquired a new position in Lumexa Imaging in the 4th quarter worth $15,954,000. Finally, Federated Hermes Inc. purchased a new position in Lumexa Imaging in the 4th quarter valued at about $8,325,000.

About Lumexa Imaging

We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).